CureVac expected to receive up to 252 million euros from the German Federal Ministry of Research for further COVID-19 vaccine development and production capacity expansion
CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials, has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to 252 million euros to support the development of its COVID-19 vaccine candidate.
Read more ...
Sinovac reports preliminary Phase I/II results of COVID-19 vaccine in elderly volunteers
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or "CoronaVac," shows good safety and immunogenicity on healthy adults aged 60 and above from its phase I/II clinical studies conducted in China, which is comparable to the result in healthy adults aged from 18 to 59 in the earlier studies.
Read more ...
Free EDC software for non-profit COVID-19 related studies
Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies. The platform is made available for the agile collection of clinical data, remote patient monitoring and customizable collaborative process for the management of intensive therapies and relocation of patients according to hospital availability.
Read more ...
AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company's core pharmaceutical manufacturing, supply chain, and delivery operations using AWS's portfolio of cloud services.
Read more ...
Merz to create three independent, customer-focused healthcare businesses to drive growth
Merz, a global, diversified healthcare company, has announced plans for a new business structure that will enable the company to better address customer and patient needs, shorten innovation cycles and capitalize on new market opportunities.
Read more ...
APRINOIA Therapeutics awarded grant from The Michael J. Fox Foundation for Parkinson's Research
APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been awarded are search grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.
Read more ...
Merz delivers double-digit growth in strategic business areas
Merz, a global leader in aesthetics and neurotoxins, showed substantial growth across both of its strategic focus areas at the end of its most recently completed fiscal year 2017/18. Merz's aesthetics and specialty neurology businesses both increased by 19 percent versus prior year, excluding foreign exchange impact. Together, these two areas now account for 67 percent of the company's healthcare revenue.
Read more ...